Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Barbara Holzer, Broadcast Manager
w. (202) 588-7716
bholzer@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

Symone Sanders, Communications Officer, Global Trade Watch division
w. (202) 454-5108
ssanders@citizen.org

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

Sept. 19, 2012        

FDA’s ‘Minor Deletions’ Policy Violates Freedom of Information Act, Should Be Revoked

GAO Told Agency 20 Years Ago That Policy Violates Letter and Spirit of Transparency Law

WASHINGTON, D.C. – The Food and Drug Administration (FDA) must stop its longstanding practice of redacting portions of documents released to Freedom of Information Act (FOIA) requesters without giving requesters an immediate right to appeal within the agency, Public Citizen said in a petition sent to the agency today. The practice violates FOIA.

The FDA has a written policy stipulating that “minor deletions” from documents are not formal denials of information requests and, therefore, do not trigger a requester’s immediate right to appeal. The agency instead requires requesters to make a second request for “reconsideration” of any deletions before being allowed to appeal. If a requester does not do so, the FDA administratively closes the FOIA request without ever making a final determination. The agency does not define “minor deletions,” but in practice it relies on the policy to delete substantial portions – sometimes full pages – of documents.

Public Citizen’s petition urges the FDA to immediately revoke the “minor deletions” policy.

“The FDA’s policy is a blatant violation of FOIA,” said Julie A. Murray, attorney for Public Citizen and a signatory of the petition. “FOIA establishes that withholding any information responsive to a FOIA request constitutes a partial denial, entitling requesters to an administrative appeal. Forcing requesters to make two attempts just to get a proper response to a FOIA request is at odds with the streamlined FOIA process required by Congress.”

 The FDA’s failure to correctly classify releases with “minor deletions” as partial denials also calls into question the accuracy of data that the FDA provides to the public in its FOIA compliance reports, the petition said. As detailed in the petition, in 2011, FDA classified 97 percent of its dispositions as full releases, as opposed to releases in part or full denials. If the FDA includes responses with “minor deletions” among those full FOIA releases – as its deletions policy suggests it does – then the FDA’s record of responding to FOIA requests through full disclosure is artificially, and perhaps grossly, inflated.

The FDA has long known that the deletions policy is legally questionable. More than two decades ago, the Government Accountability Office (then the General Accounting Office) advised the agency to rescind its deletion policy, saying that it “creates a procedure for requesters that is not authorized by FOIA.”

Although the agency contends that the policy helps speed the processing of FOIA requests, there is seemingly no reason why it would take any longer for the agency to formally deny a request in part and give requesters the immediate ability to appeal, as other agencies already do.

“The agency’s current policy is contrary to law, unnecessary to serve FOIA requesters, and ultimately does a disservice to FOIA’s commitment to transparency,” Murray said. “It is past time for the FDA to revoke it.”

To read Public Citizen’s petition, http://www.citizen.org/documents/Petition-to-FDA-to-Revoke-Deletions-Policy-for-FOIA-Processing.pdf.

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.